Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Volume 6 Issue 9, September 2006

From The Editors

Top of page ⤴

Research Highlight

Top of page ⤴

In the News

    • Edward Wawrzynczak
    In the News
Top of page ⤴

Research Highlight

Top of page ⤴

In Brief

Top of page ⤴

Review Article

  • The ARF tumour suppressor can activate p53-dependent transcriptional pathways by inhibiting the ubiquitin ligase MDM2. However, ARF has been reported to have p53-independent activities. How important are these activities in tumorigenesis? This Review critically appraises the current data.

    • Charles J. Sherr
    Review Article
  • Hepatocellular carcinoma (HCC) is highly lethal and has a high incidence worldwide. However, at present there is only a basic understanding of the genetic, cellular and environmental mechanisms that drive HCC pathogenesis. What is known, and what are the challenges and opportunities?

    • Paraskevi A. Farazi
    • Ronald A. DePinho
    Review Article
  • Polymers can be conjugated to anticancer drugs and proteins to improve their therapeutic index. Some such conjugates are in routine clinical use and there are exciting advances in development, such as polymer-based combination therapies.

    • Ruth Duncan
    Review Article
  • Several small-molecule inhibitors and monoclonal antibodies are now approved for the therapy of various cancers. Focusing on the example of the epidermal growth factor receptor inhibitors, this Review compares and contrasts these two classes of agents.

    • Kohzoh Imai
    • Akinori Takaoka
    Review Article
Top of page ⤴

Opinion

  • Drugs that target mTOR (mammalian target of rapamycin) have entered clinical trials for cancer treatment. However, current mTOR inhibitors have an unexpectedly complex mechanism of action. Can our emerging knowledge of this pathway be used to develop more effective mTOR-targeted therapies?

    • David M. Sabatini
    Opinion
  • Multiple mutations and alterations in the cancer genome lead to the deregulation of various cell-signalling pathways that control cell function. Can molecular-profiling studies be used to fully understand this complexity and provide an opportunity to link pathway deregulation with potential therapeutic strategies?

    • Andrea H. Bild
    • Anil Potti
    • Joseph R. Nevins
    Opinion
Top of page ⤴

Corrigendum

Top of page ⤴

Erratum

Top of page ⤴

Search

Quick links